Evotec (ADR)
Combines discovery, development and biologics manufacturing for pharmaceutical and biotechnology partners.
Something off on this page? Send us feedback.
Profile
Provides discovery, preclinical development and biologics services through collaborations with pharmaceutical and biotechnology customers. Its two reporting segments pair a shared R&D platform with Just – Evotec Biologics.
Offers drug discovery, preclinical development and manufacturing capabilities through partnerships with pharmaceutical and biotechnology customers. Discovery Services, Development & Manufacturing Services and Cyprotex ADME-Tox Solutions support work from disease understanding through development.
Just – Evotec Biologics adds biologics design, development and manufacturing capabilities, including the J.DESIGN platform. The business expanded through the acquisition of Just Biotherapeutics and complements small-molecule and biologics work across an international site network.
Reporting is organized around Discovery & Preclinical Development and Just – Evotec Biologics. The operating model is being simplified through footprint and capacity optimization, while delivery remains structured around externally partnered research and development programs.
Company facts
Key statistics
Year to date −39.6% · Average volume (30d) 58.3K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 15, 2026 | H.C. Wainwright | Reiterate | Buy | $7 | $4 | |
| Jul 15, 2026 | Macquarie | Target | $2 | |||
| Jul 14, 2026 | Cowen & Co. | Downgrade | Buy | Hold | ||
| Jun 29, 2026 | William Blair | Downgrade | Market Perform |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$0.05 | −$0.17 | −275.4% | $174.5M | $166.7M | −4.5% | −7.76% |
| May 6, 2026Q1 FY26 | −$0.15 | −$0.48 | −217.9% | $206.2M | $216.5M | +5.0% | −5.86% |
| Apr 8, 2026Q1 FY26 | $0.21 | $0.05 | −74.0% | $328.8M | $347.6M | +5.7% | −2.60% |
| Nov 5, 2025Q3 FY25 | −$0.14 | −$0.14 | −1.4% | $239.9M | $192.0M | −20.0% | −1.19% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $231.7M | $198.4M | $189.9M | $290.7M | $184.5M | $169.0M | |
| Gross profit | $31.5M | $10.0M | −$71.8K | $90.1M | −$1.8M | −$1.9M | |
| Operating income | −$23.2M | −$32.2M | −$51.6M | $27.9M | −$65.3M | −$60.2M | |
| Net income | −$36.6M | −$50.4M | −$49.9M | $16.8M | −$143.6M | −$54.9M | |
| Diluted EPS | −$0.10 | −$0.14 | −$0.14 | $0.05 | −$0.41 | −$0.15 | |
| Gross margin | 13.6% | 5.0% | -0.0% | 31.0% | -1.0% | -1.1% | |
| Operating margin | -10.0% | -16.2% | -27.2% | 9.6% | -35.4% | -35.6% |
Fiscal years (4-quarter sums)FY21 $716.1M · FY22 $870.7M · FY23 $905.4M · FY24 $923.4M · FY25 $910.7M
Revenue by product · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $539.5M · Total debt $551.4M · Total assets $1.82B · Shareholders' equity $771.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 355.24M · Float 336.88M · 94.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Triton GP HoldCo SARL | 17.73M | 9.99% | 13D | Oct 29, 2025 |
| MAK Capital One L.L.C. | 12.68M | 7.10% | 13D | May 1, 2026 |
| Mubadala Investment Co PJSC | 4.60M | 1.29% | 13F | May 15, 2026 |
| DCF Advisers, LLC | 1.07M | 0.30% | 13F | May 11, 2026 |
| WCM Investment Management, LLC | 627.3K | 0.18% | 13F | May 7, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Charles River Laboratories
Broad preclinical CRO and biologics-services overlap
- Recursion Pharmaceuticals
AI-native drug-discovery platform rival
- Schrödinger
Physics-based computational molecular-discovery rival
- AbCellera Biologics
Technology platform for antibody-medicine discovery
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Evotec (ADR) | $1.91 | −0.51% | $678.5M | — | — | 0.8 | −17.3% |
| Charles River Laboratories | $291.50 | +0.04% | $14.04B | — | 23.7 | 3.5 | −2.7% |
| Recursion Pharmaceuticals | $3.35 | +0.60% | $1.75B | — | — | 31.9 | −61.8% |
| Schrödinger | $19.67 | −0.15% | $1.47B | — | — | 5.7 | +7.5% |
| AbCellera Biologics | $11.37 | +0.24% | $3.47B | — | — | 52.4 | −76.3% |
| Median | — | 23.7 | 18.8 | −32.2% |